I'M ALSO STILL WATCHING AND PATIENTLY WAITING

So what happened to everybody?

I'm buying a house - closing tomorrow----
and I'm not selling these shares ---
they will be worth their weight in gold.....
and IMO, very soon...

Copied from another board yesterday and worth reading:

The uplisting on MTRE is pending and likely to be complete in a short time (expected to be within two weeks).

Once the uplist is done, the three company acquisitions that have been arranged will be completed, and the LifeHealth spin-off divvy can proceed. This involves giving a FREE share of a second, separate company to existing shareholders of MTRE at a ratio of 1:1. This is like a gift!

When all is said and done, shareholders will own shares in two OTCBB companies, both with solid business plans. MTRE will be focused on research and marketing and will be immediately profitable after the closing of the acquisitions. LifeHealth has plans in place including products to market in the non-prescription dental care market, and is exopected to also be profitable in short-order.

There are likely only a handful of days during which MTRE shares can be bought before the uplisting is done.... at bargain prices, IMO. Further info in the I-Box on the MTRE board.

Now you can't say that you weren't told! Do your own DD.

Thanks for posting the CSBR news redsox.
Looks real good to me. Pre-clinical testing of their own drug. Looks like other bios' can use this drug for their own testing. Anyone else posted to their own boards yet? Any opinions?
LINK:
http://www.championsbiotechnology.com/news.html

This company will be worth a fortune once they receive their DOT approval. Those that can stand the wait will be justly rewarded. Those that can't will go on to other things. With little invested, IMO this is worth the risk and the wait.

Holding strong - waiting patiently. IMO, this little gem will take off soon.

Today's Events - Bouncing back...

This was posted on another message board:

Getting back to the value of this stock
Based on the early morning conference call and webcast - IMO - the drug works; the clinicals will continue; and the partner PRX is positive, and is up for the day.

The weak hands that knew nothing about this drug just ran for the hills - thus putting this stock price on sale for the next few days.

Those that sold after hours at .60 are already probably wishing that they waited.

I didn't wait. I bought more, averaging down substantially. Thanks for today's sale.

IMO, especially at today's prices - this is a big money maker....

It would have been nice to make big $$$ today -- but all is not lost -- just delayed....

Sidransky's CSBR and Imclone news
LINK:
http://www.championsbiotechnology.com/news.html

Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs


ARLINGTON, Va., May 7, 2008 /PRNewswire-FirstCall via COMTEX/ -- Champions Biotechnology, Inc. (CSBR:CSBR
News, chart, profile, more
Last:

CSBR, , ) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced that it has established an agreement with ImClone Systems Incorporated for the preclinical evaluation of certain therapeutic antibodies in ImClone's clinical development pipeline. As part of the agreement, ImClone will utilize Champions Biotechnology's Biomerk Tumorgrafts(TM) in the initial preclinical evaluation.
"Studies suggest that our Biomerk Tumorgrafts provide an accelerated and more predictive platform for the evaluation of oncology drugs. The platform also enables biomarker discovery that we expect will benefit us as we facilitate partnerships between therapeutic and diagnostic companies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "ImClone Systems has an impressive antibody pipeline and we are pleased to be working with them to evaluate such promising oncology therapeutic candidates."
For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com .
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits Champions Biotechnology to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.

CSBR and today's Imclone news:
LINK:
http://www.championsbiotechnology.com/news.html

Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs


ARLINGTON, Va., May 7, 2008 /PRNewswire-FirstCall via COMTEX/ -- Champions Biotechnology, Inc. (CSBR:CSBR
News, chart, profile, more
Last:

CSBR, , ) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced that it has established an agreement with ImClone Systems Incorporated for the preclinical evaluation of certain therapeutic antibodies in ImClone's clinical development pipeline. As part of the agreement, ImClone will utilize Champions Biotechnology's Biomerk Tumorgrafts(TM) in the initial preclinical evaluation.
"Studies suggest that our Biomerk Tumorgrafts provide an accelerated and more predictive platform for the evaluation of oncology drugs. The platform also enables biomarker discovery that we expect will benefit us as we facilitate partnerships between therapeutic and diagnostic companies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "ImClone Systems has an impressive antibody pipeline and we are pleased to be working with them to evaluate such promising oncology therapeutic candidates."
For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com .
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits Champions Biotechnology to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.

CSBR up strong on today's Imclone news:
LINK:
http://www.championsbiotechnology.com/news.html

Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs


ARLINGTON, Va., May 7, 2008 /PRNewswire-FirstCall via COMTEX/ -- Champions Biotechnology, Inc. (CSBR:CSBR
News, chart, profile, more
Last:

CSBR, , ) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced that it has established an agreement with ImClone Systems Incorporated for the preclinical evaluation of certain therapeutic antibodies in ImClone's clinical development pipeline. As part of the agreement, ImClone will utilize Champions Biotechnology's Biomerk Tumorgrafts(TM) in the initial preclinical evaluation.
"Studies suggest that our Biomerk Tumorgrafts provide an accelerated and more predictive platform for the evaluation of oncology drugs. The platform also enables biomarker discovery that we expect will benefit us as we facilitate partnerships between therapeutic and diagnostic companies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "ImClone Systems has an impressive antibody pipeline and we are pleased to be working with them to evaluate such promising oncology therapeutic candidates."
For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com .
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits Champions Biotechnology to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.

MWM, Welcome back to CSBR...
What's your target?

Fringe,
What's your technical analysis on CSBR's news this morning?

How's the chart looking now?

Sidransky's other company - CSBR:
LINK:
http://www.championsbiotechnology.com/ne...

Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs


Last update: 8:30 a.m. EDT May 7, 2008Print E-mail RSS Disable Live Quotes

ARLINGTON, Va., May 7, 2008 /PRNewswire-FirstCall via COMTEX/ -- Champions Biotechnology, Inc. (CSBR:CSBR
News, chart, profile, more

CSBR, , ) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced that it has established an agreement with ImClone Systems Incorporated for the preclinical evaluation of certain therapeutic antibodies in ImClone's clinical development pipeline. As part of the agreement, ImClone will utilize Champions Biotechnology's Biomerk Tumorgrafts(TM) in the initial preclinical evaluation.
"Studies suggest that our Biomerk Tumorgrafts provide an accelerated and more predictive platform for the evaluation of oncology drugs. The platform also enables biomarker discovery that we expect will benefit us as we facilitate partnerships between therapeutic and diagnostic companies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "ImClone Systems has an impressive antibody pipeline and we are pleased to be working with them to evaluate such promising oncology therapeutic candidates."
For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com .
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits Champions Biotechnology to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.

IMCLONE AND CSBR AGREEMENT:
LINK:
http://www.championsbiotechnology.com/ne...

Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs


Last update: 8:30 a.m. EDT May 7, 2008Print E-mail RSS Disable Live Quotes

ARLINGTON, Va., May 7, 2008 /PRNewswire-FirstCall via COMTEX/ -- Champions Biotechnology, Inc. (CSBR:CSBR
News, chart, profile, more
Last:



CSBR, , ) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced that it has established an agreement with ImClone Systems Incorporated for the preclinical evaluation of certain therapeutic antibodies in ImClone's clinical development pipeline. As part of the agreement, ImClone will utilize Champions Biotechnology's Biomerk Tumorgrafts(TM) in the initial preclinical evaluation.
"Studies suggest that our Biomerk Tumorgrafts provide an accelerated and more predictive platform for the evaluation of oncology drugs. The platform also enables biomarker discovery that we expect will benefit us as we facilitate partnerships between therapeutic and diagnostic companies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "ImClone Systems has an impressive antibody pipeline and we are pleased to be working with them to evaluate such promising oncology therapeutic candidates."
For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com .
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits Champions Biotechnology to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.

NEWS - CSBR and IMCLONE Agreement Established
Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs


Last update: 8:30 a.m. EDT May 7, 2008Print E-mail RSS Disable Live Quotes

ARLINGTON, Va., May 7, 2008 /PRNewswire-FirstCall via COMTEX/ -- Champions Biotechnology, Inc. (CSBR:champions biotechnology inc com par $0.001
News, chart, profile, more
Last: 1.30+0.02+1.56%

3:48pm 05/06/2008

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
CSBR 1.30, +0.02, +1.6%) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced that it has established an agreement with ImClone Systems Incorporated for the preclinical evaluation of certain therapeutic antibodies in ImClone's clinical development pipeline. As part of the agreement, ImClone will utilize Champions Biotechnology's Biomerk Tumorgrafts(TM) in the initial preclinical evaluation.
"Studies suggest that our Biomerk Tumorgrafts provide an accelerated and more predictive platform for the evaluation of oncology drugs. The platform also enables biomarker discovery that we expect will benefit us as we facilitate partnerships between therapeutic and diagnostic companies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "ImClone Systems has an impressive antibody pipeline and we are pleased to be working with them to evaluate such promising oncology therapeutic candidates."
For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com .
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits Champions Biotechnology to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.
This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-KSB for the fiscal year ended April 30, 2007 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Biotechnology's expectations, except as required by law.
CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE: www.championsbiotechnology.com
SOURCE Champions Biotechnology, Inc.
http://www.championsbiotechnology.com

Copyright (C) 2008 PR Newswire. All rights reserved

ACEL Announces Retirement of Chief Executive Officer
http://www.snl.com/irweblinkx/news.aspx?IID=4104784

Press Release ALFACELL CORPORATION (NASDAQ - ACEL)
Alfacell Announces Retirement of Chief Executive Officer

Company Release - 04/28/2008 08:30

SOMERSET, N.J., April 28 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that Kuslima Shogen, the company's chief executive officer and scientific founder, will retire from the company on or before March 31, 2009. The company also announced that the royalty agreement between Ms. Shogen and Alfacell has been terminated.

The termination of the royalty agreement between Alfacell and Ms. Shogen could reduce payments from the Company to Ms. Shogen by an estimated $20 million over the next 10 years, if the company's lead compound, ONCONASE(R), is granted marketing approval by the U.S. Food and Drug Administration (FDA).

Under the terms of the retirement agreement between the company and Ms. Shogen, Ms. Shogen will continue to receive her current salary for a period of two years after she steps down as chief executive officer. In exchange for the termination of the royalty agreement, Ms. Shogen will receive a cash bonus, an additional cash bonus upon receiving marketing approval by the FDA of ONCONASE for the treatment of malignant mesothelioma, a significant stock option grant that vests upon such FDA approval of ONCONASE, cash payments for the first two years following approval of ONCONASE, and cash payments from Alfacell in the event aggregate annual net sales of ONCONASE exceed $100 million.

"Tina's contributions to Alfacell and the science behind ONCONASE have been immeasurable," said David Sidransky, M.D., Alfacell's chairman. "Her dedication and commitment are unmatched and I know that I speak for everyone at Alfacell in offering congratulations as she moves on to a well-earned retirement."

In addition to the retirement of Ms. Shogen, the company announced that Lawrence A. Kenyon has been named president. Mr. Kenyon joined Alfacell in January 2007 as executive vice president, chief financial officer and corporate secretary. He was promoted to chief operating officer and elected to the board of directors in November 2007. The change in responsibilities is consistent with the efforts of the board of directors to develop a succession plan that allows for a smooth leadership transition upon the potential marketing approval of ONCONASE.

"It is a comfort for me to entrust the further development and potential commercialization of our exciting pipeline to Mr. Kenyon," said Ms. Shogen. "It has been a privilege to be part of Alfacell where I have experienced the rare opportunity to make an important scientific contribution and achieve the realization of my life's work."

"Our focus has begun to shift towards the necessary steps to grow Alfacell and maximize value for our shareholders," added Mr. Kenyon. "The termination of the royalty agreement will allow us to enhance our ability to increase investment in our promising technology platform. We are excited about the future of Alfacell, and I would like to congratulate Tina and commend her for the sound scientific foundation she has built for us."

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to a Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in the outcome of the company's ongoing Phase IIIb clinical trial for its lead product, the company's ability to secure necessary approvals from regulatory agencies, uncertainties involving the ability of the company to finance research and development activities and its ongoing operations, potential challenges to or violations of patents, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media Contact: Investor Contact:
David Schull or Wendy LauTimothy EngelRusso PartnersRusso Partners
212-845-4271 212-845-4242
David.Schull@russopartnersllc.comTimothy.Engel@russopartnersllc.comWendy.Lau@russopartnersllc.com
SOURCE Alfacell Corporation

Dr. Sidransky's companies always seem to have some positive happenings.

CSBR is no exception.

IMO, we'll see more movement in the days to come.

I have no doubt that this will be on a major exchange soon.

CSBR ON THE MOVE YESTERDAY.
Any thoughts for today...

CSBR up 30 points yesterday.
Good buy signals are showing.
Any thoughts would be appreciated.

CSBR earns an overall TradingDay.com buy rating
of 64%:

link:
http://quotes.barchart.com/texpert.asp?sym=CSBR&code=BTDY" target="_blank">http://www.tradingday.com/tbs.html?http://quotes.barchart.com/texpert.asp?sym=CSBR&code=BTDY



CSBR - CHAMPIONS BIOTECHNLG (OTCBB)

Date Open High Low Last Change Volume % Change
04/23/08 1.1900 1.5000 1.1900 1.4000 +0.3000 28800 +27.27%

Composite Indicator
Trend Spotter TM Hold

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Buy

Short Term Indicators Average: 100% - Buy
20-Day Average Volume - 6265

Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Sell
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 50% - Buy
50-Day Average Volume - 8720

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Sell

Long Term Indicators Average: 33% - Buy
100-Day Average Volume - 7741

Overall Average: 64% - Buy

Price Support Pivot Point Resistance

1.4000 1.0533 1.3633 1.6733

LOL, it amazes me though...

Earlier today CSBR announced that someone invested $2.5 million dollars @ $1.75, and at the close today, someone is asking $1.35.

IMO, this stock is heading towards a major exchange before years' end with $4 plus.

Time to grab the cheap shares while you can.

Always nice, and may just be another CSBR upswing.
Here is a copy of a post from the ACEL message board that hits the nail right on the head:
Posted by: jdoo
In reply to: None Date:4/23/2008 9:08:40 AM
Post #of 1870

This is great news for common holders for the following reasons:

1 - This financing is ACCRETIVE to the common shareholders, with the restricted stock being sold at a 59% premium to yesterdays closing price.

2 - The $2.5 million represents a 4.3% ownership stake. Hopefully we will be able to figure out who has stepped up into such a significant ownership role. The identity of the mystery investor may provide additional clues about where the company is headed. I would speculate that a well off friend of the good doctor put the money up due to reasons identified in #3 below.

3 - It appears that the company has avoided vulture financing as the investment is not structured as preferred stock, convertible debt, or priced at a level which is severely dilutive to the public common holders. Again it is my speculation that the company has something pretty impressive in the pipeline for them to be able to secure additional funds on such advantageous terms.

Fringe, CSBR is moving on today's news...
What's your TA read here?
Where can we go from here?

Lefty18, you are right about CSBR - this is only the beginning...

Any doubt that this will be on a major exchange soon??

Great news from CSBR - stock moving strong:

HUGE NEWS
link:
http://www.championsbiotechnology.com/news.html

Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
Apr 23, 2008 8:30:00 AM
View Additional ProfilesARLINGTON, Va., April 23 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, announced today the completion of a $2,500,000 private financing. Under the terms of the private investment, Champions Biotechnology issued 1,428,572 restricted shares of the Company's common stock at $1.75 per share. There were no fees or other expenses related to the funding.

"Dr. David Sidransky, Champions Biotechnology's Chairman, has established a compelling vision and a high potential business. We are very pleased to have successfully completed this early strategic financing on favorable terms" said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "In addition to the cash reserve that we have generated from operations this fiscal year, this investment is expected to enable us to accelerate the development of the Company's preclinical platform, advance the development of our chemotherapeutic drug candidate and accelerate growth of our Personalized Oncology and Preclinical EValuation businesses."

After the investment, Champions Biotechnology has a total of 33,247,717 issued and outstanding common shares. For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com .

Your post on the incredible value of CSBR's huge news today hits the nail right on the head.

Seems clear that CSBR will be on a major exchange - $4 plus before years' end.

Where do you think this unique puppy is going?

Would like to hear your additional thoughts on the future.

Again, thanks for your great post.

CONGRATS to all CSBR longs....

Fringe - You are right, Today's CSBR news is absolutely huge!
Here is a post from the CSBR message board that nails the value of the news perfectly:

Posted by: jdoo
In reply to: None Date:4/23/2008 9:08:40 AM
Post #of 1869

This is great news for common holders for the following reasons:

1 - This financing is ACCRETIVE to the common shareholders, with the restricted stock being sold at a 59% premium to yesterdays closing price.

2 - The $2.5 million represents a 4.3% ownership stake. Hopefully we will be able to figure out who has stepped up into such a significant ownership role. The identity of the mystery investor may provide additional clues about where the company is headed. I would speculate that a well off friend of the good doctor put the money up due to reasons identified in #3 below.

3 - It appears that the company has avoided vulture financing as the investment is not structured as preferred stock, convertible debt, or priced at a level which is severely dilutive to the public common holders. Again it is my speculation that the company has something pretty impressive in the pipeline for them to be able to secure additional funds on such advantageous terms.
__________________________________
Looks clear that CSBR will be on a major exchange before the end of the year. $4 plus is coming soon - maybe much more...

Scottrade is showing:
Bid: .6006
ASK: .7357

Sorry, but i cannot cut and paste it.

Question regarding Level II and also Total View:

I'm using Scottrade, but CCWW will not show up on either Level II or Total View. It appears that the pinks are not available from Scottrade.

What is everyone here using?

CCWW - Good Morning to all,
I came onboard yesterday. I've been watching this for a while. Everything looks positive for forward movement next week, and for the forseeable future.
Good Luck to all.
Now - I'm committed to enjoy in your fun.

ACEL Team Receives Prestigious Reward

The Landon Foundation-AACR INNOVATOR Award for International Collaboration in Cancer Research at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.
We are pleased to inform you that Michele Carbone, M.D., Ph.D., Alfacell’s chairman of the thoracic cancer advisory board (TCAB) and a world-renowned mesothelioma researcher at the University of Hawaii’s Cancer Research Center of Hawaii, Harvey I. Pass, M.D., a member of Alfacell’s TCAB and a professor of surgery and chief of the division of thoracic surgery and thoracic oncology at NYU School of Medicine and Comprehensive Cancer Center, and their team, were presented The Landon Foundation-AACR INNOVATOR Award for International Collaboration in Cancer Research at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.
The team of international collaborators has discovered a unique mesothelioma epidemic in three Turkish villages and has demonstrated that it is caused by a genetic predisposition to mineral fiber carcinogenesis, a gene-environment interaction. These findings and additional research may be applied to understand other geographic areas and communities worldwide to help prevent this deadly form of cancer and help find new life-saving treatments.

The AACR INNOVATOR grant (two-year $100,000 grant) will be applied to additional research for their study.

We, here at Alfacell, congratulate Drs. Carbone and Pass, and their team on receiving this prestigious award and look forward to their continued support with research on the ONCONASE® (ranpirnase) program and mesothelioma.

Please access the news release by going to: http://www.aacr.org/home/public--media/news-releases.aspx?d=1027



Lawrence A. Kenyon

COO and CFO

Alfacell Corporation

Press Release: Onconase by ACEL could be a radiation sensitizer

Company Release - 04/14/2008 08:30
link:
http://www.snl.com/irweblinkx/news.aspx?IID=4104784

SOMERSET, N.J., April 14 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that Dr. Intae Lee with the University of Pennsylvania has reported that Alfacell's ONCONASE (ranpirnase) could be a promising radiation sensitizer for lung cancer treatment. Dr. Lee presented the pre-clinical in vivo and in vitro data in a poster at the 2008 American Association of Cancer Research (AACR) Annual Meeting being held April 12 - 16 in San Diego.

In the poster titled "The inhibition of radiation repair by ranpirnase +/- I-buthionine sulfoximide on lung cancer," Dr. Lee provided pre-clinical evidence that ONCONASE +/- I-buthionine sulfoximide significantly increased the radiation-induced growth delay of lung tumors in vivo without increases in skin reaction, compared to radiation alone. Additionally, in vivo and in vitro data presented indicated that ONCONASE significantly increased apoptosis (programmed cell death) in several human non-small cell lung cancer (NSCLC) cell lines (A549, NCI-H1975 and HOP-62). Dr. Lee and his team of researchers also showed that the radiation repair mechanisms known as sub-lethal damage repair (SLDR) and potentially lethal damage repair (PLDR), which lead to radiation resistance in tumors, were significantly inhibited by ONCONASE in vitro.

"Our research suggests potential utility of ONCONASE as a radiotherapy enhancer for the treatment of NSCLC patients," said Dr. Lee. "It is important to overcome PLDR as it can ultimately lead to radiation resistance. One of our key findings is the inhibiting impact of ONCONASE on the PLDR mechanism, which is a pre-requisite to developing a radiotherapy enhancer."

Kuslima Shogen, Alfacell's chief executive officer, added: "This work by Dr. Lee and his team provides further evidence of the potential for ONCONASE to mitigate the resistance that often develops in, and confounds the treatment of NSCLC."

About ONCONASE(R)

ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media Contact: Investor Contact:
David Schull or Wendy LauTimothy EngelRusso PartnersRusso Partners
212-845-4271 212-845-4242
David.Schull@russopartnersllc.comTimothy.Engel@russopartnersllc.comWendy.Lau@russopartnersllc.com
SOURCE Alfacell Corporation

Cover Story is out on ACEL's Onconase:

THIS IS THE DRUG DISCOVERY & DEVELOPMENT MAGAZINE COVER STORY - JUST OUT

Here is the link:
http://www.dddmag.com/Article-Conquering-Cancer-Resistance.aspx

News Just Out. New cancer drug Onconase just completed PIII B FDA Trials.

Any thoughts or insignts here?

ACEL Press Release
link:
http://www.snl.com/irweblinkx/file.aspx?IID=4104784&FID=5853286


Press Release ALFACELL CORPORATION (NASDAQ - ACEL)
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program

Company Release - 04/02/2008 08:30

SOMERSET, N.J., April 2, 2008 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that it has confirmed that 316 evaluable events (patient deaths) have occurred in the confirmatory Phase IIIb clinical trial of its lead compound, ONCONASE (ranpirnase), for the treatment of patients with unresectable malignant mesothelioma (UMM). In accordance with the statistical plan for the trial, the company has begun the process necessary to conduct the formal statistical analyses required to complete the final sections of the ONCONASE rolling New Drug Application (NDA).

The trial was designed to show a statistically significant improvement in overall survival for UMM patients who were treated with a combination of ONCONASE and doxorubicin as compared to UMM patients who were treated with doxorubicin as a single agent. Enrollment in the ONCONASE Phase IIIb clinical trial closed on Sept. 30, 2007. A total of 428 patients were enrolled in the trial.

Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa, the branded product division of Par Pharmaceuticals, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with BL&H Co. Ltd. for Korea, Taiwan and Hong Kong, USP Pharma Spolka Z.O.O., an affiliate of US Pharmacia, for Eastern Europe, and GENESIS Pharma, S.A. for Southeastern Europe.

ONCONASE has been granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the U.S. Food and Drug Administration (FDA). Additionally, ONCONASE has been granted orphan-drug designation in the European Union and Australia.

About ONCONASE(R)

ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to the Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media Contact: Investor Contact:
David Schull or Wendy LauTimothy EngelRusso PartnersRusso Partners
212-845-4271 212-845-4242
David.Schull@russopartnersllc.comTimothy.Engel@russopartnersllc.comWendy.Lau@russopartnersllc.com
SOURCE Alfacell Corporation

Contact: Media, David Schull, David.Schull@russopartnersllc.com, or Wendy Lau, Wendy.Lau@russopartnersllc.com, +1-212-845-4271; or Investors, Timothy Engel, +1-212-845-4242, Timothy.Engel@russopartnersllc.com, all of Russo Partners

Click here for Printer-Friendly Version

ACEL Press Release
link:
http://www.snl.com/irweblinkx/file.aspx?IID=4104784&FID=5853286


Press Release ALFACELL CORPORATION (NASDAQ - ACEL)
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program

Company Release - 04/02/2008 08:30

SOMERSET, N.J., April 2, 2008 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that it has confirmed that 316 evaluable events (patient deaths) have occurred in the confirmatory Phase IIIb clinical trial of its lead compound, ONCONASE (ranpirnase), for the treatment of patients with unresectable malignant mesothelioma (UMM). In accordance with the statistical plan for the trial, the company has begun the process necessary to conduct the formal statistical analyses required to complete the final sections of the ONCONASE rolling New Drug Application (NDA).

The trial was designed to show a statistically significant improvement in overall survival for UMM patients who were treated with a combination of ONCONASE and doxorubicin as compared to UMM patients who were treated with doxorubicin as a single agent. Enrollment in the ONCONASE Phase IIIb clinical trial closed on Sept. 30, 2007. A total of 428 patients were enrolled in the trial.

Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa, the branded product division of Par Pharmaceuticals, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with BL&H Co. Ltd. for Korea, Taiwan and Hong Kong, USP Pharma Spolka Z.O.O., an affiliate of US Pharmacia, for Eastern Europe, and GENESIS Pharma, S.A. for Southeastern Europe.

ONCONASE has been granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the U.S. Food and Drug Administration (FDA). Additionally, ONCONASE has been granted orphan-drug designation in the European Union and Australia.

About ONCONASE(R)

ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to the Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media Contact: Investor Contact:
David Schull or Wendy LauTimothy EngelRusso PartnersRusso Partners
212-845-4271 212-845-4242
David.Schull@russopartnersllc.comTimothy.Engel@russopartnersllc.comWendy.Lau@russopartnersllc.com
SOURCE Alfacell Corporation

Contact: Media, David Schull, David.Schull@russopartnersllc.com, or Wendy Lau, Wendy.Lau@russopartnersllc.com, +1-212-845-4271; or Investors, Timothy Engel, +1-212-845-4242, Timothy.Engel@russopartnersllc.com, all of Russo Partners

Click here for Printer-Friendly Version

Patents.........

Acceptional credentials to the new Management Team and Board.

Here is a link to a patent by Hidalgo, which may have been acquired by CSBR in February 2007.

http://www.wipo.int/patentscopedb/en/fetch.jsp?LANG=ENG&DBSELECT=PCT&SERVER_TYPE=19-10&SORT=1213192-KEY&TYPE_FIELD=256&IDB=0&IDOC=1393973&C=10&ELEMENT_SET=B&RESULT=13&TOTAL=67&START=1&DISP=25&FORM=SEP-0/HITNUM,B-ENG,DP,MC,AN,PA,ABSUM-ENG&SEARCH_IA=US2006014449&QUERY=%28PA%2fhidalgo%29+

One Day these patents will make history....

Short Lived - For a minute there yesterday, i thought we had an oral ct deal.....one day soon...

This news blackout IMO is good news. If they had anything to hide, they would hide it in a meaningless press release.
No news in this case - is good news. Load up at these cheap prices, sooner then later, we may see $2 - $3.

IMO something may be up, as the price is today....I can't find any new articles - anyone with some info??.....